The lack of tumor mutation burden and neoantigen were thought to contribute to the lack of CTLA‐4 and PD1/PD‐L1 immune checkpoint‐targeted immunotherapy of PCa. This evidence concerns the gene CD274 and posterior cortical atrophy.